BUZZ - Barclays upgrades Estée Lauder rating to "Overweight", stock price rises
路透社2026/10/05 09:26October 5th - The stock price of cosmetics manufacturer Estée Lauder (EL.N) rose 2.2% in pre-market trading to $93.98. Barclays upgraded the stock rating from "Neutral" to "Overweight" and raised the target price from $97 to $108. The bank stated that the company’s expected sales growth and profitability in the coming years make it one of the most attractive companies in the Global Consumer Staples Index. It was noted that, since announcing its transformation plan, the company (link) has achieved more balanced revenue growth over the past seven quarters, contrary to previous market expectations that reshaping its operating model would require significant time and investment. Growth has been recorded in all regions, and strong North America growth is expected to continue this quarter; structural changes to the operating model are expected to support continued reinvestment and gradually drive the EBIT margin up to double-digit percentage highs. The average rating given by 44 brokerages is "Buy," with a median target price of $129—data compiled by London Stock Exchange Group (LSEG). As of the last trading day’s close, the stock had declined about 12% year-to-date. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translation may be inaccurate or fail to capture the intended context, Reuters makes no representations as to the accuracy of these translations and provides them solely for reader convenience. Reuters is not responsible for any damage or losses arising from the use of automated translations.)
October 5 - ** Shares of cosmetics manufacturer Estée Lauder (EL.N) rose 2.2% in pre-market trading to $93.98
** Barclays upgraded the stock from "Neutral" to "Overweight"; price target raised from $97 to $108
** The bank stated that the company's expected sales growth and profitability in the coming years make it one of the most attractive names in the global consumer staples index
** Noted that since the announcement of the transformation plan, after seven quarters, the company (link) has achieved more balanced revenue growth, which contrasts with previous market expectations that reshaping the operating model would require substantial time and investment
** Pointed out that growth was achieved across all regions, with North America expected to maintain strong growth this quarter; structural changes to the operating model are expected to support continued reinvestment while gradually driving EBIT margins into the mid-teens
** Forty-four brokerages give an average rating of "Buy"; median price target is $129—data compiled by London Stock Exchange Group (LSEG)
** As of the previous session close, the stock is down about 12% year-to-date
(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. Due to potential errors in automated translation or lack of necessary context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Roche secures rights to Alector's Parkinson's therapy for up to $1.27 billions, Alector shares surge
Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.
Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris
08:10 AM EDT, 10/05/2026 (MT Newswires) -- Harrow (HROW) said Monday that it has closed its earlier stated acquisition of Tyrvaya from Viatris (VTRS), acquiring worldwide rights to the nasal spray, except for Japan. Harrow said that, in accordance with the terms reported in August, the company paid $30 million in cash at closing and may pay up to $70 million in sales-based milestones. Tyrvaya is an FDA-approved nasal spray for dry eye disease, Harrow said. Harrow said it expects the product to generate more than $30 million in revenue next year.
Ecarx Completes Acquisition of Flyme Software Business
08:10 AM EDT, 10/05/2026 (MT Newswires) -- Ecarx (ECX) said Monday that it has closed its acquisition of the entire Flyme software business portfolio, including the Flyme Auto in-vehicle cockpit operating system and a cross-device Flyme operating system. The company said it paid 1.8 billion Chinese renminbi ($266 million) in cash, about 70% of which was funded by syndicated bank loans from Chinese commercial banks and roughly 30% from internal sources. After closing, Ecarx said it will provide the acquired business with 200 million renminbi to support its operations. Shares of Ecarx were up 5.8% pre-bell Monday.
BUZZ - US Stock Market Dynamics - RXO, Harley-Davidson, Vistra
Search string for querying individual stock trends in the workspace: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief" newsletter: https://refini.tv/3dKUyB8 Reuters, October 5 - On Monday, U.S. stock index futures edged lower as tech stocks retreated after reaching record highs. As Treasury yields and oil prices remain elevated, investors are seeking new clues about the direction of monetary policy. .N ** RXO RXO.N: Market focus — RXO shares rose following C.H. Robinson's announcement of a 5.8 billions USD acquisition plan nL6N45R0N4 ** Harley-Davidson HOG.N: Market focus — Citi upgraded Harley-Davidson to "Buy," shares climbed nL6N45R0M3 ** GEO Group GEO.N: Spotlight — GEO gained as it sold ICE facilities for 950 millions USD and expanded its stock buyback nL6N45R0MR ** Vistra VST.N: Spotlight — Vistra rallied as it was reportedly set to receive a 4.2 billions USD U.S. nuclear loan nL4N45R0L8 ** Vaxcyte PCVX.O: Spotlight — Vaxcyte surged after positive late-stage clinical trial data for its pneumococcal vaccine nL4N45R0K0 ** Estée Lauder EL.N: Spotlight — Barclays upgraded Estée Lauder to "Overweight," shares advanced nL6N45R0HX ** PTC PTC.O: Spotlight — Schneider Electric agreed to acquire PTC for 22.6 billions USD, shares jumped nL6N45R0HV (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translation may contain errors or fail to convey the required context, Reuters does not guarantee the accuracy of automatically translated texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translation features.)
Crypto prices
More
